See more : Acropolis Infrastructure Acquisition Corp. (ACRO-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Levitee Labs Inc. (LVT.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Levitee Labs Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- PT Bank BTPN Tbk (BTPN.JK) Income Statement Analysis – Financial Results
- Princeton Technology Corporation (6129.TWO) Income Statement Analysis – Financial Results
- Vishwaraj Sugar Industries Limited (VISHWARAJ.NS) Income Statement Analysis – Financial Results
- Contemporary Amperex Technology Co., Limited (300750.SZ) Income Statement Analysis – Financial Results
- NR Instant Produce Public Company Limited (NRF.BK) Income Statement Analysis – Financial Results
Levitee Labs Inc. (LVT.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.leviteelabs.com
About Levitee Labs Inc.
Levitee Labs Inc., a multidisciplinary integrative wellness company, provides evidence-based alternative medicines and novel psychedelic therapies. The company operates through two segments, Medical Services and Selling Products. It offers treatments and medications for substance use disorders and chronic pain, such as myofascial pain, fibromyalgia, neuropathy, and chronic regional pain syndrome, as well as hepatitis-C and mental health conditions. The company operates five clinics under the Levitee Clinics name; and three pharmacies in Alberta under the Levitee Pharmacies name. In addition, it offers electronic-prescriptions in the addiction treatment space under the BlockMD name; and wholesales supplements and superfood under the Earth Circle Organics name. The company was formerly known as Fibonacci Capital Corp. and changed its name to Levitee Labs Inc. in November 30, 2020. Levitee Labs Inc. was incorporated in 2019 and is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.72M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 687.64K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 39.95% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 10.74M | 431.27K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 675.40K | 412.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 11.41M | 431.68K | 309.79K |
| Other Expenses | 0.00 | 0.00 | 268.85K | 6.18K | 0.00 |
| Operating Expenses | 0.00 | 0.00 | 11.68M | 431.68K | 309.79K |
| Cost & Expenses | 0.00 | 0.00 | 12.72M | 431.68K | 309.79K |
| Interest Income | 0.00 | 0.00 | 34.34K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 46.05K | 245.00 | 518.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 894.04K | -6.18K | 171.86K |
| EBITDA | 0.00 | 0.00 | -10.73M | -441.48K | -309.79K |
| EBITDA Ratio | 0.00% | 0.00% | -586.76% | 0.00% | 0.00% |
| Operating Income | 0.00 | 0.00 | -10.99M | -431.68K | -309.79K |
| Operating Income Ratio | 0.00% | 0.00% | -638.70% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | -378.66K | -16.47K | -516.00 |
| Income Before Tax | 0.00 | 0.00 | -11.37M | -441.73K | -310.31K |
| Income Before Tax Ratio | 0.00% | 0.00% | -660.69% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 29.12K | 16.22K | 0.00 |
| Net Income | 0.00 | 0.00 | -11.40M | -457.95K | -310.31K |
| Net Income Ratio | 0.00% | 0.00% | -662.39% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | -0.19 | -0.01 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.19 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 0.00 | 61.43M | 80.11M | 80.11M |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 | 61.43M | 80.11M | 80.11M |
Source: https://incomestatements.info
Category: Stock Reports